Companies › Materia Medica Holding
2 active drug programs in 5 registered trials: 5 Phase 3; Infectious disease, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Raphamin (MMH-407) | – | Phase 3 | Cystitis Chronic; Rhinosinusitis; Acute Respiratory Viral Infection; Bronchitis | Dec 2026 |
| Rengalin unclear - proprietary combination medication | – | Phase 3 | Cough | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06284265 | Raphamin (MMH-407) | Phase 3 | Cystitis Chronic | Infectious disease | Dec 2026 |
| NCT06901297 | Raphamin (MMH-407) | Phase 3 | Rhinosinusitis | Respiratory | Dec 2027 |
| NCT06715891 | Raphamin (MMH-407) | Phase 3 | Acute Respiratory Viral Infection | Infectious disease | Dec 2027 |
| NCT07650227 | Raphamin (MMH-407) | Phase 3 | Bronchitis | Respiratory | Dec 2028 |
| NCT07171099 | Rengalin | Phase 3 | Cough | Infectious disease | Dec 2028 |
No annotated target.
–
Laboratorio Farmaceutico SIT srl Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Jiangxi Qingfeng Pharmaceutical Zero Point Five Therapeutics MicuRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.